December 12, 2006
Product news from the 12/12/06 news brief
Millennium Pharmaceuticals received FDA approval to market Velcade for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. MCL is a relatively uncommon and aggressive form of non-Hodgkin's lymphoma for which there was no standard of care in the relapsed or refractory setting. MCL has a US prevalence of 10,000 patients. Velcade is currently the market leader in multiple myeloma for patients who have received one prior therapy.